Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: An observational study in three cohorts

Critical Care

Volumn 14, Issue 3, 2010, Pages

  Kumpf, Oliver ^a   Giamarellos Bourboulis, Evangelos J ^b,c   Koch, Alexander ^d   Hamann, Lutz ^e   Mouktaroudi, Maria ^b,c   Oh, Djin Ye ^e,f   Latz, Eicke ^g,h   Lorenz, Eva ⁱ   Schwartz, David A ^j   Ferwerda, Bart ^b   Routsi, Christina ^c   Skalioti, Chryssanthi ^c   Kullberg, Bart Jan ^b   van der Meer, Jos W M ^b   Schlag, Peter M ^e   Netea, Mihai G ^b   Zacharowski, Kai ^d   Schumann, Ralf R ^e  

^a Hanse Klinikum Stralsund   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f TUFTS MEDICAL CENTER   (United States)

^g UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF BONN   (Germany)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^j DEPARTMENT OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MYELOID DIFFERENTIATION FACTOR 88 ADAPTOR LIKE; TOLL INTERLEUKIN 1 RECEPTOR ASSOCIATED PROTEIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; INTERLEUKIN 1 RECEPTOR; MEMBRANE PROTEIN; TIRAP PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GERMANY; GRAM NEGATIVE BACTERIUM; GREECE; HEART SURGERY; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; IN VIVO STUDY; INFECTION RISK; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POPULATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURGICAL PATIENT; TERTIARY HEALTH CARE; UNIVERSITY HOSPITAL; VENTILATOR ASSOCIATED PNEUMONIA; AGED; BLOOD; CROSS INFECTION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK ASSESSMENT;

AGED; COHORT STUDIES; CROSS INFECTION; CYTOKINES; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERMANY; GREECE; HUMANS; INTENSIVE CARE UNITS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; POLYMORPHISM, GENETIC; POSTOPERATIVE PERIOD; RECEPTORS, INTERLEUKIN-1; RISK ASSESSMENT; SEPSIS; TOLL-LIKE RECEPTOR 4;

EID: 77952993918     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9047     Document Type: Article

References (46)

1. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-903.
2. Pessaux P, Msika S, Atalla D, Hay JM, Flamant Y. Risk factors for postoperative infectious complications in noncolorectal abdominal surgery: a multivariate analysis based on a prospective multicenter study of 4718 patients. Arch Surg 2003, 138:314-324. 10.1001/archsurg.138.3.314, 12611581.
3. Dinarello CA. Proinflammatory cytokines. Chest 2000, 118:503-508. 10.1378/chest.118.2.503, 10936147.
4. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993, 328:1471-1477. 10.1056/NEJM199305203282008, 8479467.
5. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826. 10.1038/nature06246, 17943118.
6. Adib-Conquy M, Cavaillon JM. Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS Lett 2007, 581:3723-3733. 10.1016/j.febslet.2007.03.074, 17428476.
7. Arcaroli J, Fessler MB, Abraham E. Genetic polymorphisms and sepsis. Shock 2005, 24:300-312. 10.1097/01.shk.0000180621.52058.e1, 16205313.
8. Beutler B. Innate immunity: an overview. Mol Immunol 2004, 40:845-859. 10.1016/j.molimm.2003.10.005, 14698223.
9. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801. 10.1016/j.cell.2006.02.015, 16497588.
10. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, Brint E, Dunne A, Gray P, Harte MT, McMurray D, Smith DE, Sims JE, Bird TA, O'Neill LA. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001, 413:78-83. 10.1038/35092578, 11544529.
11. Schröder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005, 5:156-164.
12. Hawn TR, Dunstan SJ, Thwaites GE, Simmons CP, Thuong NT, Lan NT, Quy HT, Chau TT, Hieu NT, Rodrigues S, Janer M, Zhao LP, Hien TT, Farrar JJ, Aderem A. A polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis. J Infect Dis 2006, 194:1127-1134. 10.1086/507907, 16991088.
13. Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, Ling EY, Frodsham AJ, Walley AJ, Kyrieleis O, Khan A, Aucan C, Segal S, Moore CE, Knox K, Campbell SJ, Lienhardt C, Scott A, Aaby P, Sow OY, Grignani RT, Sillah J, Sirugo G, Peshu N, Williams TN, Maitland K, Davies RJ, Kwiatkowski DP, Day NP, Yala D, Crook DW, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007, 39:523-528. 2660299, 17322885, 10.1038/ng1976.
14. Ferwerda B, Alonso S, Banahan K, McCall MB, Giamarellos-Bourboulis EJ, Ramakers BP, Mouktaroudi M, Fain PR, Izagirre N, Syafruddin D, Cristea T, Mockenhaupt FP, Troye-Blomberg M, Kumpf O, Maiga B, Dolo A, Doumbo O, Sundaresan S, Bedu-Addo G, van Crevel R, Hamann L, Oh DY, Schumann RR, Joosten LA, de la Rua C, Sauerwein R, Drenth JP, Kullberg BJ, van der Ven AJ, Hill AV, et al. Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc Natl Acad Sci USA 2009, 106:10272-10277. 2700915, 19509334, 10.1073/pnas.0811273106.
15. Ferwerda B, McCall MB, Alonso S, Giamarellos-Bourboulis EJ, Mouktaroudi M, Izagirre N, Syafruddin D, Kibiki G, Cristea T, Hijmans A, Hamann L, Israel S, ElGhazali G, Troye-Blomberg M, Kumpf O, Maiga B, Dolo A, Doumbo O, Hermsen CC, Stalenhoef AF, van Crevel R, Brunner HG, Oh DY, Schumann RR, de la Rua C, Sauerwein R, Kullberg BJ, van der Ven AJ, van der Meer JW, Netea MG. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci USA 2007, 104:16645-16650. 2034238, 17925445, 10.1073/pnas.0704828104.
16. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256. 10.1097/01.CCM.0000050454.01978.3B, 12682500.
17. Hamann L, Kumpf O, Schuring RP, Alpsoy E, Bedu-Addo G, Bienzle U, Oskam L, Mockenhaupt FP, Schumann RR. Low frequency of the TIRAP S180L polymorphism in Africa, and its potential role in malaria, sepsis, and leprosy. BMC Med Genet 2009, 10:65. 2717080, 19602285, 10.1186/1471-2350-10-65.
18. Giamarellos-Bourboulis EJ, Routsi C, Plachouras D, Markaki V, Raftogiannis M, Zervakis D, Koussoulas V, Orfanos S, Kotanidou A, Armaganidis A, Roussos C, Giamarellou H. Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock?. Crit Care 2006, 10:R76. 1550931, 16696867, 10.1186/cc4921.
19. Giamarellos-Bourboulis EJ, Zakynthinos S, Baziaka F, Papadomichelakis E, Virtzili S, Koutoukas P, Armaganidis A, Giamarellou H, Roussos C. Soluble triggering receptor expressed on myeloid cells 1 as an anti-inflammatory mediator in sepsis. Intensive Care Med 2006, 32:237-243. 10.1007/s00134-005-0017-1, 16450102.
20. Routsi C, Giamarellos-Bourboulis EJ, Antonopoulou A, Kollias S, Siasiakou S, Koronaios A, Zakynthinos S, Armaganidis A, Giamarellou H, Roussos C. Does soluble triggering receptor expressed on myeloid cells-1 play any role in the pathogenesis of septic shock?. Clin Exp Immunol 2005, 142:62-67. 1809490, 16178857, 10.1111/j.1365-2249.2005.02887.x.
21. Hamann L, Hamprecht A, Gomma A, Schumann RR. Rapid and inexpensive real-time PCR for genotyping functional polymorphisms within the Toll-like receptor -2, -4, and -9 genes. J Immunol Methods 2004, 285:281-291. 10.1016/j.jim.2003.12.005, 14980441.
22. Lorenz E, Frees KL, Schwartz DA. Determination of the TLR4 genotype using allele-specific PCR. Biotechniques 2001, 31:22-24.
23. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988, 318:727-732.
24. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005, 365:63-78. 10.1016/S0140-6736(04)17667-8, 15639681.
25. Remick DG. Pathophysiology of sepsis. Am J Pathol 2007, 170:1435-1444. 1854939, 17456750, 10.2353/ajpath.2007.060872.
26. Holmes CL, Russell JA, Walley KR. Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest 2003, 124:1103-1115. 10.1378/chest.124.3.1103, 12970043.
27. Lin MT, Albertson TE. Genomic polymorphisms in sepsis. Crit Care Med 2004, 32:569-579. 10.1097/01.CCM.0000110878.49476.42, 14758181.
28. Netea MG, van der Meer JW, van Deuren M, Kullberg BJ. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing?. Trends Immunol 2003, 24:254-258. 10.1016/S1471-4906(03)00079-6, 12738419.
29. Salomao R, Martins PS, Brunialti MK, Fernandes Mda L, Martos LS, Mendes ME, Gomes NE, Rigato O. TLR signaling pathway in patients with sepsis. Shock 2008, (30 Suppl 1):73-77. 10.1097/SHK.0b013e318181af2a, 18704004.
30. Wiersinga WJ, van't Veer C, van den Pangaart PS, Dondorp AM, Day NP, Peacock SJ, van der Poll T. Immunosuppression associated with interleukin-1R-associated-kinase-M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Crit Care Med 2009, 37:569-576. 10.1097/CCM.0b013e318194b1bf, 19114913.
31. Suleiman MS, Zacharowski K, Angelini GD. Inflammatory response and cardioprotection during open-heart surgery: the importance of anaesthetics. Br J Pharmacol 2008, 153:21-33. 2199383, 17952108, 10.1038/sj.bjp.0707526.
32. Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N, Sellevold OF, Espevik T, Sundan A. Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 2002, 105:685-690. 10.1161/hc0602.103617, 11839622.
33. Vogel SN, Fitzgerald KA, Fenton MJ. TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expression. Mol Interv 2003, 3:466-477. 10.1124/mi.3.8.466, 14993454.
34. Kagan JC, Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 2006, 125:943-955. 10.1016/j.cell.2006.03.047, 16751103.
35. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316:1628-1632. 10.1126/science.1138963, 17569868.
36. Biswas SK, Bist P, Dhillon MK, Kajiji T, Del Fresno C, Yamamoto M, Lopez-Collazo E, Akira S, Tergaonkar V. Role for MyD88-independent, TRIF pathway in lipid A/TLR4-induced endotoxin tolerance. J Immunol 2007, 179:4083-4092.
37. Dang O, Navarro L, David M. Inhibition of lipopolysaccharide-induced interferon regulatory factor 3 activation and protection from septic shock by hydroxystilbenes. Shock 2004, 21:470-475. 1282467, 15087825, 10.1097/00024382-200405000-00012.
38. Zacharowski K, Zacharowski PA, Koch A, Baban A, Tran N, Berkels R, Papewalis C, Schulze-Osthoff K, Knuefermann P, Zahringer U, Schumann RR, Rettori V, McCann SM, Bornstein SR. Toll-like receptor 4 plays a crucial role in the immune-adrenal response to systemic inflammatory response syndrome. Proc Natl Acad Sci USA 2006, 103:6392-6397. 1458888, 16606831, 10.1073/pnas.0601527103.
39. Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE, Lowry SF. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002, 186:1522-1525. 10.1086/344893, 12404174.
40. Read RC, Pullin J, Gregory S, Borrow R, Kaczmarski EB, di Giovine FS, Dower SK, Cannings C, Wilson AG. A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis 2001, 184:640-642. 10.1086/322798, 11494169.
41. Smirnova I, Mann N, Dols A, Derkx HH, Hibberd ML, Levin M, Beutler B. Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci USA 2003, 100:6075-6080. 156328, 12730365, 10.1073/pnas.1031605100.
42. Kumpf O, Hamann L, Schlag PM, Schumann RR. Pre- and postoperative cytokine release after in vitro whole blood lipopolysaccharide stimulation and frequent toll-like receptor 4 polymorphisms. Shock 2006, 25:123-128. 10.1097/01.shk.0000190823.44030.e6, 16525349.
43. Schippers EF, van 't Veer C, van Voorden S, Martina CA, le Cessie S, van Dissel JT. TNF-alpha promoter, Nod2 and toll-like receptor-4 polymorphisms and the in vivo and ex vivo response to endotoxin. Cytokine 2004, 26:16-24. 10.1016/j.cyto.2003.12.003, 15016407.
44. van der Graaf C, Kullberg BJ, Joosten L, Verver-Jansen T, Jacobs L, Van der Meer JW, Netea MG. Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Cytokine 2005, 30:264-268. 10.1016/j.cyto.2005.02.001, 15927851.
45. Calvano JE, Bowers DJ, Coyle SM, Macor M, Reddell MT, Kumar A, Calvano SE, Lowry SF. Response to systemic endotoxemia among humans bearing polymorphisms of the Toll-like receptor 4 (hTLR4). Clin Immunol 2006, 121:186-190. 10.1016/j.clim.2006.05.012, 16829202.
46. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002, 162:1028-1032. 10.1001/archinte.162.9.1028, 11996613.